Tongue cancer overview: Difference between revisions
Simrat Sarai (talk | contribs) |
Simrat Sarai (talk | contribs) |
||
| Line 49: | Line 49: | ||
==Medical Therapy== | ==Medical Therapy== | ||
The predominant therapy for tongue cancer is surgical resection. Adjunctive [[chemotherapy]], [[radiation]], chemoradiation, or [[brachytherapy]] may be required. | The predominant therapy for tongue cancer is surgical resection. Adjunctive [[chemotherapy]], [[radiation]], chemoradiation, or [[brachytherapy]] may be required.<ref name="pmid16168836">{{cite journal| author=Bourgier C, Coche-Déquéant B, Fournier C, Castelain B, Prévost B, Lefebvre JL et al.| title=Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. | journal=Int J Radiat Oncol Biol Phys | year= 2005 | volume= 63 | issue= 2 | pages= 434-40 | pmid=16168836 | doi=10.1016/j.ijrobp.2005.02.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16168836 }} </ref><ref name="pmid2807886">{{cite journal| author=McGregor AD, MacDonald DG| title=Patterns of spread of squamous cell carcinoma within the mandible. | journal=Head Neck | year= 1989 | volume= 11 | issue= 5 | pages= 457-61 | pmid=2807886 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2807886 }} </ref><ref name="pmid3220769">{{cite journal| author=McGregor AD, MacDonald DG| title=Routes of entry of squamous cell carcinoma to the mandible. | journal=Head Neck Surg | year= 1988 | volume= 10 | issue= 5 | pages= 294-301 | pmid=3220769 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3220769 }} </ref><ref name="pmid2370178">{{cite journal| author=Wendt CD, Peters LJ, Delclos L, Ang KK, Morrison WH, Maor MH et al.| title=Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. | journal=Int J Radiat Oncol Biol Phys | year= 1990 | volume= 18 | issue= 6 | pages= 1287-92 | pmid=2370178 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2370178 }} </ref> | ||
==Surgery== | ==Surgery== | ||
Surgery is the mainstay of treatment for tongue cancer. | Surgery is the mainstay of treatment for tongue cancer. | ||
Revision as of 21:26, 16 December 2015
|
Tongue cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tongue cancer overview On the Web |
|
American Roentgen Ray Society Images of Tongue cancer overview |
|
Risk calculators and risk factors for Tongue cancer overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Tongue cancer is a cancer that begins in the cells of the tongue. Approximately 25-30% of all oral cavity cancers begin in the tongue and usually begins in the cells on the top of the tongue. If the cancer begins in the front two thirds of the tongue it is considered a type of an oral cancer and if begins on the back third of the tongue it is considered a type of throat cancer. Approximately 20% of all squamous cell carcinomas of the oral cavity arise from the tongue, and approximately 75% of all tongue squamous cell carcinomas arise from the anterior two thirds of the tongue. Squamous cell carcinoma of the tongue usually arise from the ventrolateral aspect of the mid and posterior tongue, probably due to adjacent pooling of carcinogens. Squamous cell carcinoma of the tongue has tobacco smoking and alcohol ingestion as the major risk factors and spans two regions: the anterior two thirds is a common subtype of squamous cell carcinoma of the oral cavity whereas the posterior third is considered part of the oropharynx. There is no classification system established for tongue cancer. Nonsquamous cell cancers comprise fewer than 3% of all lingual malignancies. More than 90% of oral cavity cancers are squamous cell carcinomas. The majority of the other lesions are of minor salivary gland origin. Melanomas, lymphomas and sarcomas rarely occur in the tongue.[1] Genes involved in the pathogenesis of tongue cancer include TP53, c-myc, and erb-b1. On gross pathology, exophytic, ulcerative, and infiltrative growth patterns are characteristic findings of tongue cancer. Tongue cancer may be caused by either tobacco, alcohol, or human papillomavirus. Tongue cancer is caused by a point mutation in the tumor suppressor gene (TP53). Other causes of tongue cancer include areca nuts, the betel nuts or quid, use of slaked lime, and Plummer-Vinson syndrome. Tongue cancer must be differentiated from other diseases that cause malignant lesions of the oral cavity and from few non-neoplastic lesions of the oral cavity, such as lymphoma, adenoid cystic carcinoma, adenocarcinoma, mucoepidermoid carcinoma, rhabdomyosarcoma, liposarcoma, infections at the floor of mouth and mandible, and normal adenoid tissue for lesions at the base of tongue.[2] In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. There is no racial predilection to the tongue cancer.[3] The most potent risk factor in the development of oral cancer is alcohol intake, tobacco use and human papillomavirus transmitted through sexual contact. The other risk factors include history of betel quid intake, male gender, age over 55 year, ultraviolet light, Fanconi anemia, dyskeratosis congenita, lichen planus, graft-versus-host disease (GVHD), immune system suppression, mouthwash and irritation from dentures.[2] Head and neck MRI scan is diagnostic of tongue cancer. On head and neck MRI, tongue cancer is characterized by isointense to hypointense mass on T1-weighted MRI and isotense to hyperintense mass on T2-weighted MRI.[2] The predominant therapy for tongue cancer is surgical resection. Adjunctive chemotherapy, radiation, chemoradiation, or brachytherapy may be required.
Classification
There is no classification system established for tongue cancer. Nonsquamous cell cancers comprise fewer than 3% of all lingual malignancies. More than 90% of oral cavity cancers are squamous cell carcinomas. The majority of the other lesions are of minor salivary gland origin. Melanomas, lymphomas and sarcomas rarely occur in the tongue.[1]
Pathophysiology
Genes involved in the pathogenesis of tongue cancer include TP53, c-myc, and erb-b1. On gross pathology, exophytic, ulcerative, and infiltrative growth patterns are characteristic findings of tongue cancer.[4]
Causes
Tongue cancermay be caused by either tobacco, alcohol, or human papillomavirus. Tongue cancer is caused by a point mutation in the tumor suppressor gene (TP53). The other oncogenes associated with oral squamous cell cancer of tongue include c-myc and erb -b1. Other causes of tongue cancer include areca nuts, the betel nuts or quid, use of slaked lime, and Plummer-Vinson syndrome.
Differential Diagnosis
Tongue cancer must be differentiated from other diseases that cause malignant lesions of the oral cavity and from few non-neoplastic lesions of the oral cavity, such as lymphoma, adenoid cystic carcinoma, adenocarcinoma, mucoepidermoid carcinoma, rhabdomyosarcoma, liposarcoma, infections at the floor of mouth and mandible, and normal adenoid tissue for lesions at the base of tongue.[2]
Epidemiology and Demographics
In 2009, the incidence of tongue cancer was estimated to be 10,530 cases per 100,000 individuals in the United States. Males are more commonly affected with tongue cancer than females. The male to female ratio is approximately 2 to 1. The incidence of tongue cancer increases with age; the median age at diagnosis is 61 years. Approximately one-third of all diagnoses occurred in patients under the age of 55. There is no racial predilection to the tongue cancer.[3]
Risk Factors
The most potent risk factor in the development of oral cancer is alcohol intake, tobacco use and human papillomavirus transmitted through sexual contact. The other risk factors include history of betel quid intake, male gender, age over 55 year, ultraviolet light, Fanconi anemia, dyskeratosis congenita, lichen planus, graft-versus-host disease (GVHD), immune system suppression, mouthwash and irritation from dentures.[2]
Screening
According to the United States Preventive Services Task Force, screening for salivary gland tumors is not recommended.[5]
Natural History, Complications and Prognosis
If left untreated, patients with tongue cancer may progress to develop metastasis. Common complications of treatment of tongue cancer include neurotoxicity, bleeding, radiation caries, trismus, osteonecrosis, oral mucositis, chronic dysphagia, anemia, pharyngocutaneous fistula, aspiration, infections, xerostomia, taste alterations, nutritional compromise, and abnormal tooth development. Prognosis is generally good, and the five-year mortality rate of patients with stage I and II tongue cancer is approximately 89 and 95 respectively. The five- year disease specific survival rate of patients with stage III and IV cancers is 39 and 27 percent respectively.[2]
Staging
According to the TNM staging system by the American Joint Committee on Cancer, there are four stages of oral cancer based on the tumor size, lymph nodes involved, and metastasis.[2][6]
History and Symptoms
Symptoms of tongue cancer include a red or white patch on the tongue, sore throat, an ulcer or lump on the tongue, pain on swallowing, speaking, or moving the tongue, numbness in the mouth, bleeding from the tongue, pain in the ear, and pain in the mouth or tongue.
Physical Examination
Common physical examination findings of tongue cancer include otalgia, submandibular gland asymmetry, and cervical lymphadenopathy.
Laboratory Findings
Laboratory findings consistent with the diagnosis of tongue cancer include reduced CBC levels, abnormal prothrombin time (PT), abnormal activated partial thromboplastin time (aPTT), and abnormal international normalized ratio (INR).
Chest X Ray
Chest and dental x-rays may be performed to detect metastases of tongue cancer to the lungs and mandible.
CT
Head and neck CT scan may be helpful in the diagnosis of tongue cancer. Findings on CT scan suggestive of tongue cancer include soft tissue attenuation of lesions, bony erosions, and increased attenuation of involved nodes.[2]
MRI
Head and neck MRI scan is diagnostic of tongue cancer. On head and neck MRI, tongue cancer is characterized by isointense to hypointense mass on T1-weighted MRI and isotense to hyperintense mass on T2-weighted MRI.[2]
Ultrasound
Ultrasound may be performed to detect metastases of tongue cancer to cervical lymph nodes and to aid in FNAC of suspicious nodes.[2]
Other Imaging Studies
Other diagnostic studies for tongue cancer include bone scan and positron emission tomography.
Other Diagnostic Studies
Other diagnostic studies for tongue cancer include tumor biopsy and panendoscopy.
Medical Therapy
The predominant therapy for tongue cancer is surgical resection. Adjunctive chemotherapy, radiation, chemoradiation, or brachytherapy may be required.[7][8][9][10]
Surgery
Surgery is the mainstay of treatment for tongue cancer.
Primary Prevention
Effective measures for the primary prevention of tongue cancer include avoiding the use of tobacco and excessive use of alcohol.
Secondary Prevention
Secondary prevention strategies following tongue cancer include monthly follow-ups for the first 12-18 months following therapy.
References
- ↑ 1.0 1.1 Soares EC, Carreiro Filho FP, Costa FW, Vieira AC, Alves AP (2008). "Adenoid cystic carcinoma of the tongue: case report and literature review". Med Oral Patol Oral Cir Bucal. 13 (8): E475–8. PMID 18667978.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Squamous cell carcinoma of the tongue. Radiopedia(2015) http://radiopaedia.org/articles/squamous-cell-carcinoma-of-the-tongue Accessed on November 16, 2015
- ↑ 3.0 3.1 Cancer of the oral cavity and pharynx. SEER(2015) http://seer.cancer.gov/csr/1975_2012/results_merged/sect_20_oral_cavity_pharynx.pdf#search=tongue+cancer Accessed on November 28, 2015
- ↑ A. Mashberg (1978). "Erythroplasia: the earliest sign of asymptomatic oral cancer". Journal of the American Dental Association (1939). 96 (4): 615–620. PMID 0273632. Unknown parameter
|month=ignored (help) - ↑ http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=tongue+cancer Accessed on November 28, 2015.
- ↑ Staging of Sqamous cell carcinoma of the oral cavity. Radiopedia(2015) http://radiopaedia.org/articles/staging-of-squamous-cell-carcinoma-of-the-oral-cavity Accessed on November 17, 2015
- ↑ Bourgier C, Coche-Déquéant B, Fournier C, Castelain B, Prévost B, Lefebvre JL; et al. (2005). "Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma". Int J Radiat Oncol Biol Phys. 63 (2): 434–40. doi:10.1016/j.ijrobp.2005.02.014. PMID 16168836.
- ↑ McGregor AD, MacDonald DG (1989). "Patterns of spread of squamous cell carcinoma within the mandible". Head Neck. 11 (5): 457–61. PMID 2807886.
- ↑ McGregor AD, MacDonald DG (1988). "Routes of entry of squamous cell carcinoma to the mandible". Head Neck Surg. 10 (5): 294–301. PMID 3220769.
- ↑ Wendt CD, Peters LJ, Delclos L, Ang KK, Morrison WH, Maor MH; et al. (1990). "Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy". Int J Radiat Oncol Biol Phys. 18 (6): 1287–92. PMID 2370178.